Trials / Unknown
UnknownNCT02296203
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Gruppo Oncologico del Nord-Ovest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentric, phase II single-arm study in which KRAS, NRAS and BRAF wild-type, irinotecan-resistant metastatic colorectal cancer patients progressing after an initial response to a first-line cetuximab-containing therapy, receive a rechallenge third-line treatment with cetuximab plus irinotecan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cetuximab | |
| DRUG | irinotecan |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2017-06-19
- Completion
- 2018-06-15
- First posted
- 2014-11-20
- Last updated
- 2018-02-15
Locations
9 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02296203. Inclusion in this directory is not an endorsement.